Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2005
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05CH02
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:drugClass |
melatonin receptor agonist
|
| gptkbp:eliminatedIn |
urine
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:ramelteon
|
| gptkbp:halfLife |
1-2.6 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rozerem
|
| gptkbp:indication |
difficulty with sleep onset
|
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Takeda_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
selective agonist at MT1 and MT2 melatonin receptors
|
| gptkbp:metabolism |
liver (CYP1A2, CYP2C9, CYP3A4)
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
dizziness
fatigue somnolence |
| gptkbp:usedFor |
insomnia
|
| gptkbp:bfsParent |
gptkb:Takeda
gptkb:Takeda_(Japan) |
| gptkbp:bfsLayer |
6
|